Eli Lilly and Company has expanded a licencing and partnership agreement with ProQR Therapeutics to discover, develop and market new genetic medicines.
The companies entered the initial agreement in September last year.
This alliance is utilising the Axiomer ribonucleic acid (RNA) editing platform of ProQR to address ailments affecting the liver and nervous system.
So far, progresses in the platform have substantially boosted editing efficiency and advanced biodistribution in the liver and nervous system.
This has also led to new possible applications to fix known mutations and to apply protective variants in particular transcripts.
Under the expanded partnership, the firms will analyse additional applications of the Axiomer platform to unveil new therapies for diseases with great unmet medical needs.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataAs per this deal, Lilly will obtain access to further targets in the central nervous system and peripheral nervous system using the Axiomer platform.
Lilly will make an upfront payment and equity investment totalling $75m to ProQR.
Additionally, Lilly holds the option to expand the collaboration for a fee worth $50m.
The company can also choose to grant ProQR access to its delivery technology for the fully owned pipeline.
As per the prior and expanded agreements, ProQR is entitled to get research, development and commercialisation milestone payments totalling up to nearly $3.75bn, apart from tiered royalty payments on sales of products.
ProQR founder and CEO Daniel de Boer said: “Our original collaboration with Lilly, which leverages our Axiomer RNA editing technology platform, continues to progress well and we are pleased to be expanding our partnership to include additional targets, along with an option for Lilly to opt in for more.”
The latest development comes after Lilly and Sosei Heptares signed a partnership for developing small molecules that modulate new G protein-coupled receptor targets linked to diabetes and metabolic diseases.
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
